Oscar Health's Record Quarter Was a 36% Price Hike — and Its Own Guidance Books a Fourth-Quarter Loss

Oscar Health turned in the kind of quarter that makes an entire sector look healthy: $5.14 billion of revenue, up 72% year over year and roughly $420 million ahead of the $4.72 billion consensus, with a third raise to full-year guidance. Almost none of that growth came from demand. Effectuated members rose 27% to 2,691,885, while premium revenue per member per month jumped about 36% to roughly $624 — a price increase written by policy, after enhanced federal subsidies expired on Jan 1, 2026 and what consumers pay for the same plan rose by 114% or more.

Strip out the policy effect and Oscar sold roughly a quarter more lives at a third higher price. The headline describes a subsidy-expiry price shock rather than a demand cycle, and that distinction decides everything downstream: a price-driven book resets when policy resets, and Oscar's own 2027 plan is to keep paying for volume with rate.

Exchange enrollment is shrinking, not expanding. KFF counts 21.8 million paying members in 2025 and 19.2 million in 2026 — the first decline in seven years — and sees the pool falling to as few as 17.5 million in 2027. Oscar grew into that hole by capturing members that other carriers priced out of the market. This was a transfer of customers, not a rising tide.

The quarter's $178.0 million of operating profit was smaller than the single item management flagged inside it: a $250 million benefit from updated risk-adjustment estimates, reflecting Oscar's risk scores running better than the market's and modestly favorable market morbidity. Strip the true-up out and the quarter shows an operating loss of roughly $72 million. Management's caution is legitimate — it said not all favorable risk adjustment flows to the bottom line because claims follow the risk profile — but the arithmetic is the arithmetic.

The scale matters more than the quarter. Risk-adjustment transfer payables ran at about 17% of direct policy premium revenue in 2026 — roughly $2.45 billion over nine months, ten times the $236.4 million of investment income earned in the same period. Competitors' integrity programs close exactly the gap that produced Oscar's 2026 windfall, and management has already cut its 2026 transfer expectation from 20% of premiums to 17–18%.

Nine-month operating earnings of $1,265.1 million already exceed the entire full-year guidance range of $850 million to $950 million. That is arithmetic, not interpretation: the raised full-year bar embeds a fourth-quarter operating loss of $315 million to $415 million.

Oscar has guided to a fourth-quarter operating loss in each of the past two years — $147.7 million in Q4 2024 and $333.7 million in Q4 2025 — because the year's pricing must cover a full year of claims while the risk pool erodes as healthier members leave. The November raise should be read as a first-nine-months raise, not a full-year one.

The durable evidence in the print is administrative, not actuarial. Oscar's SG&A expense ratio fell to 14.0% of revenue in the third quarter from 17.5% a year earlier, and to 14.4% for the first nine months from 17.3%. Three and a half points of administrative cost on $5.14 billion of revenue is about $180 million of operating income that does not depend on the risk-transfer formula or on a policy decision in Washington.

Whether that model survives depends on volume rather than price: Oscar must hold membership while selling into 24% more counties in a pool KFF expects to shrink again in 2027, and management gave no 2027 revenue, margin or membership guidance beyond an expectation of stable enrollment and further margin expansion.

Oscar's quarter is a routing system. Of $5.14 billion of revenue, about $4.24 billion — 84.0% of premium revenue — is medical cost paid out to providers, while $91.0 million is investment income earned on the float. The money that decides the equity story sits upstream of the member: a federal risk-adjustment transfer, a pharmacy benefit manager, and a behavioral-health manager.

Oscar keeps the upside of a repriced, shrinking market and pushes excess cost risk to providers, because its contracts let providers repay it when medical costs exceed the target loss ratio. That is a good business while pricing runs ahead of trend and a poor one when it does not — which is exactly the question 2027 asks.

Here is where the post-midterm consensus gets it backwards. Democrats now control both chambers, and restoring enhanced subsidies has moved from possible to probable — but for Oscar, restoration is a threat rather than a rescue: subsidized members pay a fraction of the premium while better-funded rivals return with the integrity tools that erase Oscar's risk edge. The three things that produced 2026's record — price up, competition weakened, displaced members to capture — are the same three things a subsidy bill would take away.

Three tests decide this. January 2027 tests whether membership holds. Mid-2027 tests the transfer rate, where each point is worth roughly $200 million of operating earnings on an estimated $21 billion of 2027 premium — about a quarter of what Oscar guided for 2026. And before 2028, Congress decides whether the cliff stays or is repaired. 2027 will be a repricing year, not a growth year, and the only question that matters is which side of that trade Oscar's cost structure leaves you on.

At roughly five times guided operating earnings, with $4.5 billion of cash sitting inside regulated insurance subsidiaries against $7.3 billion of claims and other liabilities, the market prices Oscar's 2026 earnings as if the risk transfer never repeats. That is a rational price for a melting ice cube and a cheap price for a cost structure running at 14% of revenue. The two views cannot both be right, which is why the stock has traded between $10.69 and $38.50 over the past year.